Drug Profile
Filgrastim biosimilar - Apotex/Intas Biopharmaceuticals
Alternative Names: Grastofil; Neukine; Recombinant human granulocyte colony stimulating factor - Intas Biopharmaceuticals; Recombinant human granulocyte colony stimulating factor biosimilar - SciVac Ltd; SciLocyteLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Intas Biopharmaceuticals
- Developer Apotex; Intas Biopharmaceuticals; SciVac Ltd
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 14 Mar 2019 No recent reports of development identified for preregistration for Neutropenia in USA (IV)
- 14 Mar 2019 No recent reports of development identified for preregistration for Neutropenia in USA (SC)
- 13 Feb 2015 Preregistration for Neutropenia in USA (IV; SC)